More on Pfizer's (PFE -0.8%) Q3: In addition to EPS and revenue beats, the company raised...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

More on Pfizer's (PFE -0.8%) Q3: In addition to EPS and revenue beats, the company raised full-year EPS guidance and boosted its share repurchase program. But the loss of patent protection on major drugs is taking a bite out of results, as earnings in its primary care division fell 7% Y/Y. Pfizer will lose patent protection on its blockbuster heart drug Lipitor this month.